Heard On The Street: Dealers Spot Action In Archean Chemical, SRF, Indian Hotels, And More

The Sensex and Nifty are hovering near their day's highs as markets experience subdued trading on Monday. NDTV Profit India has been tracking the action in the top dealing rooms of India's financial capital, and this edition of ‘Heard On The Street' provides you with buzzing action on stocks like Archean Chemical, SRF, Indian Hotels, Epigral, Balmer Lawrie and AU Small Finance Bank.

Heard On The Street provides readers with what well-informed investors, especially HNIs, FIIs, DIIs, and mutual funds, are buying and selling in the stock market. It also tracks the latest unconfirmed/unverified chatter around stocks and/or sectors.

AU Small Finance Bank

Dealers indicate that strong demand was seen in the block today. Half of the offer was subscribed by long-only funds. Large mutual funds like HDFC, ICICI Pru, and Tata were among the top buyers.

Archean Chemical

Multiple dealing rooms have been recommending a ‘buy' call to their clients in anticipation of a potential uptick in bromine prices. For Archean Chemical, bromine is the key product, contributing over 60% of the volumes.

SRF and PNB Housing

Dealers indicate that their buy flows are on the domestic institutional desk for both counters.

Indian Hotels

There are buy flows on the domestic institutional desk, but dealers indicate that smart investors are selling ahead of Q4 numbers.

Epigral and Balmer Lawrie

Large influential HNIs have started to accumulate these counters as per dealing room checks.

ABB India

Dealers indicate delivery-based selling on the FII desk.

Disclaimer: The mentioned stocks capture NDTV Profit's dealing room channel checks during trading hours. The information provided is for informational purposes. However, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, or suitability of the information. This content does not constitute financial, investment, or trading advice and should not be construed as a recommendation to buy, sell, or hold any securities.